Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Y-mAbs Therapeutics, Inc.
  6. News
  7. Summary
    YMAB   US9842411095

Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Sell: Y-mAbs Therapeutics

12/08/2021 | 05:22pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
All news about Y-MABS THERAPEUTICS, INC.
05/26Y MABS THERAPEUTICS : mAbs Announces Naxitamab Chemoimmunotherap Investigational Trial for..
PU
05/26Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/26Y-mAbs Phase 2 Trial of Naxitamab Chemoimmunotherapy for High-Risk Neuroblastoma Achiev..
MT
05/26Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuro..
AQ
05/26Y-mAbs Therapeutics, Inc Announces Naxitamab Chemoimmunotherapy Investigational Trial f..
CI
05/19Y-mAbs Therapeutics Appoints President Thomas Gad Interim CEO
MT
05/19Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/10Wedbush Adjusts Price Target for Y-mAbs Therapeutics to $21 From $28, Maintains Outperf..
MT
05/10TRANSCRIPT : Y-mAbs Therapeutics, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/09Y-MABS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
More news
Analyst Recommendations on Y-MABS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 63,4 M - -
Net income 2022 -89,4 M - -
Net cash 2022 197 M - -
P/E ratio 2022 -5,77x
Yield 2022 -
Capitalization 510 M 510 M -
EV / Sales 2022 4,93x
EV / Sales 2023 3,59x
Nbr of Employees 148
Free-Float 87,7%
Chart Y-MABS THERAPEUTICS, INC.
Duration : Period :
Y-mAbs Therapeutics, Inc. Technical Analysis Chart | YMAB | US9842411095 | MarketScreener
Technical analysis trends Y-MABS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 11,66 $
Average target price 27,83 $
Spread / Average Target 139%
EPS Revisions
Managers and Directors
Thomas Gad President & Chief Executive Officer
Bo Kruse CFO, Secretary. Treasurer & Executive VP
James Irvin Healy Chairman
Torben Lund-Hansen Chief Technology Officer & Senior Vice President
Steen Lisby Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
Y-MABS THERAPEUTICS, INC.-28.07%510
GILEAD SCIENCES, INC.-10.76%81 280
REGENERON PHARMACEUTICALS, INC.9.70%74 647
VERTEX PHARMACEUTICALS24.65%70 008
BIONTECH SE-35.24%40 574
WUXI APPTEC CO., LTD.-22.01%39 958